Chunhai Hao, MD, PhD
Bicentennial Professor of Pathology & Laboratory Medicine
Dr. Hao completed his MD, PhD and neuropathology residency training and became a certified neuropathologist and Fellow of Royal College of Physicians and Surgeons of Canada (FRCPC) in 1997. He started his physician-scientist career at University of Alberta and then moved to Emory University and McGill University. In January 2018, he joined the Indiana University School of Medicine as the Bicentennial Chair and tennured Professor of Pathology and Laboratory Medicine and Neurological Surgery.
His research focuses on ubiquitin and SUMO modification and regulation of proteins in human diseases. His team has revealed how ubiquitination regulates apoptotic pathway in cancers (Bellail et al. Cancer Discovery 2012, 2:140) and SUMO1 conjugation controls the cancer cell cycle (Bellail et al. Nature Communications 2014, 5:4234). Recently, his team identified the first small molecule degraders of SUMO1 protein and unveiled the targeted SUMO1 protein ubiquitination and degradation pathway through CRISPR-CAS9 genome wide screening. He co-founded the start-up biotech company HB Therapeutics, Inc. for commercialization of small molecule degraders as new anticancer drugs.
His research has been funded by various agencies including Canadian Institutes of Health Research (CIHR) and National Institutes of Health (NIH). He has been awarded the Clinical Investigator of the Alberta Heritage Foundation for Medical Research and Distinguished Cancer Clinician & Scholar of the Georgia Cancer Coalition.
Pathology And Laboratory Med
R2 E378 PATH
Titles & Appointments
- Professor of Neurological Surgery
- Bicentennial Chair, Pathology and Laboratory Medicine
Dr. Hao and Dr. Bellail have established a joined research team on the posttranslational modification of ubiquitin (UB) and SUMO (small ubiquitin-like modifier) for the discovery of UB and SUMO-targeted small molecules as therapeutic agents. The team has identified the small molecule degraders of SUMO1 protein as new anticancer drugs and small molecule solubilizers of amyloid protein as anti-aging drugs. They have co-founded a start-up company for clinical development and commercialization of these therapeutic agents. Their research is currently funded by NIH R01 and SBIR grants.